COMPANY OVERVIEW

AOBiome is a Boston and San Francisco based biotech company focused on transforming human health through products that restore ammonia-oxidizing bacteria (AOBs) which current hygiene practices have stripped from the modern microbiome.

---

LOCATION

Cambridge, MA, USA

---

THERAPEUTIC AREAS

Inflammatory Disease

---

WEBSITE

https://aobiome.com/

---

CAREER WEBSITE

https://aobiome.com/careers

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

May 16, 2023

AOBiome announces the publication of positive Phase 2b results in The Lancet's eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus

Apr 6, 2023

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

Sep 20, 2022

Additional Study Augments the Results of AOBiome's Successful 547 Patient Phase 2b Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis and Moderate-to-Severe Pruritus using its B244 investigational drug

Feb 22, 2022

AOBiome Therapeutics' topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and Appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)

Nov 16, 2021

AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic

For More Press Releases

---